Agency Business briefs

Share this article:
Palio formalized its partnership with Zemoga, an interactive shop, and launched a blog: Pixels and Pills ( The blog's stated mission is to use the site as a “platform for dialogue, insight and idea sharing” around the topics of technology and communications. The blogs contributors are DJ Edgerton, Sven Larsen and Russ Ward of Zemoga, and Dan Licht and Guy Mastrion of Palio.

In order to increase its global outreach, MicroMass joined Worldwide Partners, Inc. (WPI), an international network of independent agencies. WPI consists of 94 agencies and services clients in 54 countries. The network contains only two US pharmaceutical agencies, according to a statement. Based in Denver, Colorado, WPI generates over $4.1 billion in capitalized billings, the statement said.

Merkle promoted Pete Mehr from VP and client team leader to chief strategy officer for the agency's healthcare marketing practice, which launched earlier this year. He will oversee the execution of physician relationship marketing programs, consumer/patient relationship programs and market research initiatives for Merkle's clients, according to a statement.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?